This cross-sectional study examined the physiological effects of two active chairs (AC1: had the feature to pedal and slide forward; AC2: was a multiaxial chair) compared to a traditional office chair and standing workstation. Twenty-four healthy participants computed at each of the workstations for 60 min. The active protocol was to alternate between a pedalling/side-to-side motion and sliding forward/front-to-back motion to the sound of a metronome operating at 40 bpm. The participants' physiological effects were recorded using near-infrared spectroscopy (NIRS); electrodermal activity (EDA) and a heart rate (HR) monitor for each collection period. Statistical analysis was conducted using a repeated measures analysis of variance for within-task and between-workstation comparisons. A Tukey's post hoc analysis was calculated for significant findings. Both active chairs significantly increased oxygenated blood in the gastrocnemius and participants' heart rate and EDA (stress) levels were affected slightly by task and time. However, participants felt more "productive" sitting in the control chair than in either of the active chairs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.apergo.2022.103741 | DOI Listing |
Biomater Adv
January 2025
Chair of Functional Materials, Department of Materials Science, Saarland University, 66123 Saarbrücken, Germany.
Antimicrobial surfaces are a promising approach to reduce the spread of pathogenic microorganisms in various critical environments. To achieve high antimicrobial functionality, it is essential to consider the material-specific bactericidal mode of action in conjunction with bacterial surface interactions. This study investigates the effect of altered contact conditions on the antimicrobial efficiency of Cu surfaces against Escherichia coli and Staphylococcus aureus.
View Article and Find Full Text PDFJ Neurol
January 2025
Division of Child Neurology, Children's Hospital of Philadelphia, Departments of Neurology and Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Background: The presented study identified the appropriate ocrelizumab dosing regimen for patients with pediatric-onset multiple sclerosis (POMS).
Methods: Patients with POMS aged 10-17 years were enrolled into cohort 1 (body weight [BW] < 40 kg, ocrelizumab 300 mg) and cohort 2 (BW ≥ 40 kg, ocrelizumab 600 mg) during a 24-week dose-exploration period (DEP), followed by an optional ocrelizumab (given every 24 weeks) extension period.
Primary Endpoints: pharmacokinetics, pharmacodynamics (CD19 B-cell count); secondary endpoint: safety; exploratory endpoints: MRI activity, protocol-defined relapses, Expanded Disability Status Scale (EDSS) score change.
Heliyon
January 2025
Institute of Chemistry, University of Tartu, 14a Ravila St., 50411, Tartu, Estonia.
Elevated concentrations of pharmaceutically active compounds (PhACs) in the water bodies are posing a serious threat to the aquatic microbiota and other organisms. In this context, anaerobic ammonium oxidizing (anammox) bacteria carry a great potential to degrade PhACs through their innate metabolic pathways. This study investigates the influence of short-term exposure to lower and higher concentrations (0.
View Article and Find Full Text PDFMol Pharm
January 2025
Laboratory of Thermodynamics, Department of Biochemical and Chemical Engineering, TU Dortmund University, Emil-Figge-Street 70, Dortmund 44227, Germany.
Lyophilization remains a key method for preserving sensitive biopharmaceuticals such as monoclonal antibodies. Traditionally, stabilization mechanisms have been explained by vitrification, which minimizes molecular mobility in the lyophilized cake, and water replacement, which restores molecular interactions disrupted by water removal. This study proposes a novel design strategy that combines water activity and glass-transition temperature as the main indicators to predict long-term stability in lyophilized formulations.
View Article and Find Full Text PDFVaccine
January 2025
Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA. Electronic address:
The mpox virus (MPXV) came to global attention with the 2022 global outbreak. Current vaccination and post-exposure prophylaxis against MPXV consists of live vaccinia whole virus-based vaccines including ACAM2000®, JYNNEOS™, and LC16m8 originally developed against smallpox. Here, we analyzed 152 vaccinia-derived peptides we identified by mass spectrometry for homology with MPXV-1 and MPXV-2 sequences to evaluate their potential relevance to MPXV-specific immunity.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!